Financhill
Sell
45

NVS Quote, Financials, Valuation and Earnings

Last price:
$121.09
Seasonality move :
2.25%
Day range:
$120.34 - $121.28
52-week range:
$96.06 - $124.83
Dividend yield:
3.3%
P/E ratio:
18.94x
P/S ratio:
4.58x
P/B ratio:
6.23x
Volume:
1.6M
Avg. volume:
1.4M
1-year change:
8.36%
Market cap:
$239.1B
Revenue:
$51.7B
EPS (TTM):
$6.39

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
NVS
Novartis AG
$14.1B $2.37 8.26% 47.31% $113.44
AMGN
Amgen
$8.9B $5.24 5.03% 3.13% $313.56
AZN
AstraZeneca PLC
$14.1B $1.10 8.83% 84.16% $85.27
GILD
Gilead Sciences
$7B $1.95 -0.13% 51.38% $116.85
RHHBY
Roche Holding AG
$18.8B -- -- -- $46.42
SNY
Sanofi SA
$11.7B $1.00 -17.69% 92.33% $62.57
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
NVS
Novartis AG
$121.04 $113.44 $239.1B 18.94x $3.99 3.3% 4.58x
AMGN
Amgen
$297.03 $313.56 $159.7B 27.10x $2.38 3.12% 4.71x
AZN
AstraZeneca PLC
$71.74 $85.27 $222.4B 28.81x $1.05 2.16% 4.07x
GILD
Gilead Sciences
$112.09 $116.85 $139.4B 23.60x $0.79 2.78% 4.92x
RHHBY
Roche Holding AG
$40.28 $46.42 $256.3B 28.67x $1.39 3.45% 3.69x
SNY
Sanofi SA
$48.55 $62.57 $118.7B 17.32x $2.20 4.52% 2.49x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
NVS
Novartis AG
43.44% 0.140 13.49% 0.50x
AMGN
Amgen
90.24% -0.268 34.26% 0.74x
AZN
AstraZeneca PLC
42.02% 0.141 13.05% 0.69x
GILD
Gilead Sciences
56.56% 0.135 17.9% 1.00x
RHHBY
Roche Holding AG
52.17% -0.143 16.91% 1.19x
SNY
Sanofi SA
20.53% -0.268 15.28% 0.26x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
NVS
Novartis AG
$10.4B $4.7B 18.39% 30.96% 34.34% $2.2B
AMGN
Amgen
$5.2B $1.2B 8.85% 97.08% 33.08% $980M
AZN
AstraZeneca PLC
$11.3B $3.7B 10.93% 19.55% 27.61% $2.7B
GILD
Gilead Sciences
$5.1B $2.5B 13.82% 32.29% 28.63% $1.7B
RHHBY
Roche Holding AG
-- -- 12.15% 23.8% -- --
SNY
Sanofi SA
$8.1B $2.6B 6.79% 8.47% 22.36% $2.2B

Novartis AG vs. Competitors

  • Which has Higher Returns NVS or AMGN?

    Amgen has a net margin of 26.48% compared to Novartis AG's net margin of 21.23%. Novartis AG's return on equity of 30.96% beat Amgen's return on equity of 97.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    NVS
    Novartis AG
    76.31% $1.82 $67.9B
    AMGN
    Amgen
    63.58% $3.20 $63.6B
  • What do Analysts Say About NVS or AMGN?

    Novartis AG has a consensus price target of $113.44, signalling downside risk potential of -6.28%. On the other hand Amgen has an analysts' consensus of $313.56 which suggests that it could grow by 5.56%. Given that Amgen has higher upside potential than Novartis AG, analysts believe Amgen is more attractive than Novartis AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVS
    Novartis AG
    0 8 2
    AMGN
    Amgen
    12 15 2
  • Is NVS or AMGN More Risky?

    Novartis AG has a beta of 0.599, which suggesting that the stock is 40.101% less volatile than S&P 500. In comparison Amgen has a beta of 0.491, suggesting its less volatile than the S&P 500 by 50.876%.

  • Which is a Better Dividend Stock NVS or AMGN?

    Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 3.3%. Amgen offers a yield of 3.12% to investors and pays a quarterly dividend of $2.38 per share. Novartis AG pays 63.85% of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.

  • Which has Better Financial Ratios NVS or AMGN?

    Novartis AG quarterly revenues are $13.6B, which are larger than Amgen quarterly revenues of $8.1B. Novartis AG's net income of $3.6B is higher than Amgen's net income of $1.7B. Notably, Novartis AG's price-to-earnings ratio is 18.94x while Amgen's PE ratio is 27.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.58x versus 4.71x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVS
    Novartis AG
    4.58x 18.94x $13.6B $3.6B
    AMGN
    Amgen
    4.71x 27.10x $8.1B $1.7B
  • Which has Higher Returns NVS or AZN?

    AstraZeneca PLC has a net margin of 26.48% compared to Novartis AG's net margin of 21.46%. Novartis AG's return on equity of 30.96% beat AstraZeneca PLC's return on equity of 19.55%.

    Company Gross Margin Earnings Per Share Invested Capital
    NVS
    Novartis AG
    76.31% $1.82 $67.9B
    AZN
    AstraZeneca PLC
    83.51% $0.94 $70.9B
  • What do Analysts Say About NVS or AZN?

    Novartis AG has a consensus price target of $113.44, signalling downside risk potential of -6.28%. On the other hand AstraZeneca PLC has an analysts' consensus of $85.27 which suggests that it could grow by 18.85%. Given that AstraZeneca PLC has higher upside potential than Novartis AG, analysts believe AstraZeneca PLC is more attractive than Novartis AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVS
    Novartis AG
    0 8 2
    AZN
    AstraZeneca PLC
    7 2 0
  • Is NVS or AZN More Risky?

    Novartis AG has a beta of 0.599, which suggesting that the stock is 40.101% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.141%.

  • Which is a Better Dividend Stock NVS or AZN?

    Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 3.3%. AstraZeneca PLC offers a yield of 2.16% to investors and pays a quarterly dividend of $1.05 per share. Novartis AG pays 63.85% of its earnings as a dividend. AstraZeneca PLC pays out 65.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NVS or AZN?

    Novartis AG quarterly revenues are $13.6B, which are larger than AstraZeneca PLC quarterly revenues of $13.6B. Novartis AG's net income of $3.6B is higher than AstraZeneca PLC's net income of $2.9B. Notably, Novartis AG's price-to-earnings ratio is 18.94x while AstraZeneca PLC's PE ratio is 28.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.58x versus 4.07x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVS
    Novartis AG
    4.58x 18.94x $13.6B $3.6B
    AZN
    AstraZeneca PLC
    4.07x 28.81x $13.6B $2.9B
  • Which has Higher Returns NVS or GILD?

    Gilead Sciences has a net margin of 26.48% compared to Novartis AG's net margin of 19.72%. Novartis AG's return on equity of 30.96% beat Gilead Sciences's return on equity of 32.29%.

    Company Gross Margin Earnings Per Share Invested Capital
    NVS
    Novartis AG
    76.31% $1.82 $67.9B
    GILD
    Gilead Sciences
    76.9% $1.04 $44B
  • What do Analysts Say About NVS or GILD?

    Novartis AG has a consensus price target of $113.44, signalling downside risk potential of -6.28%. On the other hand Gilead Sciences has an analysts' consensus of $116.85 which suggests that it could grow by 4.24%. Given that Gilead Sciences has higher upside potential than Novartis AG, analysts believe Gilead Sciences is more attractive than Novartis AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVS
    Novartis AG
    0 8 2
    GILD
    Gilead Sciences
    16 11 0
  • Is NVS or GILD More Risky?

    Novartis AG has a beta of 0.599, which suggesting that the stock is 40.101% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.290, suggesting its less volatile than the S&P 500 by 71.014%.

  • Which is a Better Dividend Stock NVS or GILD?

    Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 3.3%. Gilead Sciences offers a yield of 2.78% to investors and pays a quarterly dividend of $0.79 per share. Novartis AG pays 63.85% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

  • Which has Better Financial Ratios NVS or GILD?

    Novartis AG quarterly revenues are $13.6B, which are larger than Gilead Sciences quarterly revenues of $6.7B. Novartis AG's net income of $3.6B is higher than Gilead Sciences's net income of $1.3B. Notably, Novartis AG's price-to-earnings ratio is 18.94x while Gilead Sciences's PE ratio is 23.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.58x versus 4.92x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVS
    Novartis AG
    4.58x 18.94x $13.6B $3.6B
    GILD
    Gilead Sciences
    4.92x 23.60x $6.7B $1.3B
  • Which has Higher Returns NVS or RHHBY?

    Roche Holding AG has a net margin of 26.48% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 30.96% beat Roche Holding AG's return on equity of 23.8%.

    Company Gross Margin Earnings Per Share Invested Capital
    NVS
    Novartis AG
    76.31% $1.82 $67.9B
    RHHBY
    Roche Holding AG
    -- -- $78.4B
  • What do Analysts Say About NVS or RHHBY?

    Novartis AG has a consensus price target of $113.44, signalling downside risk potential of -6.28%. On the other hand Roche Holding AG has an analysts' consensus of $46.42 which suggests that it could grow by 15.24%. Given that Roche Holding AG has higher upside potential than Novartis AG, analysts believe Roche Holding AG is more attractive than Novartis AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVS
    Novartis AG
    0 8 2
    RHHBY
    Roche Holding AG
    2 6 0
  • Is NVS or RHHBY More Risky?

    Novartis AG has a beta of 0.599, which suggesting that the stock is 40.101% less volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.358%.

  • Which is a Better Dividend Stock NVS or RHHBY?

    Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 3.3%. Roche Holding AG offers a yield of 3.45% to investors and pays a quarterly dividend of $1.39 per share. Novartis AG pays 63.85% of its earnings as a dividend. Roche Holding AG pays out 92.43% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NVS or RHHBY?

    Novartis AG quarterly revenues are $13.6B, which are larger than Roche Holding AG quarterly revenues of --. Novartis AG's net income of $3.6B is higher than Roche Holding AG's net income of --. Notably, Novartis AG's price-to-earnings ratio is 18.94x while Roche Holding AG's PE ratio is 28.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.58x versus 3.69x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVS
    Novartis AG
    4.58x 18.94x $13.6B $3.6B
    RHHBY
    Roche Holding AG
    3.69x 28.67x -- --
  • Which has Higher Returns NVS or SNY?

    Sanofi SA has a net margin of 26.48% compared to Novartis AG's net margin of 17.65%. Novartis AG's return on equity of 30.96% beat Sanofi SA's return on equity of 8.47%.

    Company Gross Margin Earnings Per Share Invested Capital
    NVS
    Novartis AG
    76.31% $1.82 $67.9B
    SNY
    Sanofi SA
    72.76% $0.80 $101.3B
  • What do Analysts Say About NVS or SNY?

    Novartis AG has a consensus price target of $113.44, signalling downside risk potential of -6.28%. On the other hand Sanofi SA has an analysts' consensus of $62.57 which suggests that it could grow by 28.88%. Given that Sanofi SA has higher upside potential than Novartis AG, analysts believe Sanofi SA is more attractive than Novartis AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVS
    Novartis AG
    0 8 2
    SNY
    Sanofi SA
    5 3 0
  • Is NVS or SNY More Risky?

    Novartis AG has a beta of 0.599, which suggesting that the stock is 40.101% less volatile than S&P 500. In comparison Sanofi SA has a beta of 0.489, suggesting its less volatile than the S&P 500 by 51.088%.

  • Which is a Better Dividend Stock NVS or SNY?

    Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 3.3%. Sanofi SA offers a yield of 4.52% to investors and pays a quarterly dividend of $2.20 per share. Novartis AG pays 63.85% of its earnings as a dividend. Sanofi SA pays out 84.6% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NVS or SNY?

    Novartis AG quarterly revenues are $13.6B, which are larger than Sanofi SA quarterly revenues of $11.2B. Novartis AG's net income of $3.6B is higher than Sanofi SA's net income of $2B. Notably, Novartis AG's price-to-earnings ratio is 18.94x while Sanofi SA's PE ratio is 17.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.58x versus 2.49x for Sanofi SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVS
    Novartis AG
    4.58x 18.94x $13.6B $3.6B
    SNY
    Sanofi SA
    2.49x 17.32x $11.2B $2B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Oklo Stock Double?
Will Oklo Stock Double?

Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…

Why a $5 Stock Is Suddenly a Cash Machine
Why a $5 Stock Is Suddenly a Cash Machine

If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…

Is Roku Stock Undervalued Now?
Is Roku Stock Undervalued Now?

At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
42
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Alerts

Buy
55
INKT alert for Jul 15

MiNK Therapeutics [INKT] is down 24.16% over the past day.

Sell
48
NEGG alert for Jul 15

Newegg Commerce [NEGG] is down 22.94% over the past day.

Buy
77
VBTX alert for Jul 15

Veritex Holdings [VBTX] is down 0.46% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock